Factor XII Inhibition Program

About Aronora

Aronora is a private, clinical-stage biotech pioneering a new approach in cardio-hematology by targeting specific coagulation factors like Factor XI, Factor XII, and Protein C. The company's pipeline includes first-in-class and best-in-class antibody and biologic candidates for conditions such as acute ischemic stroke, catheter-associated thrombosis, and hemodialysis. With a strong foundation in genetic and mechanistic research, Aronora aims to provide safer, more effective anti-thrombotic therapies for large, underserved patient populations at risk of life-threatening blood clots.

Therapeutic Areas